Syngene International Ltd. · NSE:SYNGENE
Syngene International — Investor Presentation (April 2022)
43 slides from Syngene International's investor presentation, April 2022
Slide 1: Investor Presentation April 2022
Investor Presentation April 2022
Slide 2: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 3: Contents
Contents 1 Operating Highlights 2 Syngene – Putting Science to Work 3 Strategic Advantages 4 Financials 5 Shareholding and Share Information Putting Science to Work 3
Slide 4: Operating Highlights
Ml Operating Highlights Syngene
Slide 5: Q4 FY22 performance
Q4 FY22 performance Operating Highlights Q4 Q4 Financial Highlights • Growth was driven by solid delivery across all divisions. • Revenue from operations increased by 15% year-on-year Development Services had a particularly strong quarter as it caught up on projects postponed due to supply chain del
Slide 6: Full year performance FY22
Full year performance FY22 Operating Highlights FY22 Financial Highlights • Syngene’s Integrated Drug Discovery (IDD) platform, made a positive contribution to Discovery Services during the year as the number of • Revenue from operations increased by 19% year-on-year IDD projects increased by ~40% c
Slide 7: FY23 guidance
FY23 guidance Parameter FY23 Guidance Revenue from operations Expected to grow at least in the mid-teens In light of positive demand environment for CRO and CDMO services, expect to step up investments in new scientific capabilities, IT, digitisation and commercial activities. This step up in invest
Slide 8: Syngene – Putting Science to Work
2 Syngene – Putting Science to Work
Slide 9: Putting science to work: Who we are and what we do
Putting science to work Who we are and what we do Integrated solution provider Working with clients from Innovative culture driven by the Well established in scientific across research, development around the world to find expertise of a highly qualified research and development, manufacturing cover
Slide 10: Syngene key facts and figures
Syngene key facts and figures 420+ 15 400+ 2 Mn sq. ft. active clients collaborations Patents of World class infrastructure, with top 20 pharmaceutical held with clients qualified to meet companies international standards Rs. 40,381 Mn Rs. 26,570 Mn Rs. 4,211 Mn ~5300 Cum. Investment FY22 Revenue FY
Slide 11: International accreditations
International accreditations • USFDA,OHSAS 18001, • GLP, cGMP, AAALAC & CPCSEA Certified Facilities • CAP accreditation, ISO/IEC 27001:2013 accreditation • EMA and PMDA approved, AAALAC Accredited facility • The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:20
Slide 12: Our experience spans multiple industry segments and partnerships with global leaders
Our experience spans multiple industry segments and partnerships with global leaders across the world Large & Emerging Animal Consumer Mid-Sized AgroChem BioPharma (EBP) Health products BioPharma Clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs) Global foo
Slide 13: Our journey so far
Our journey so far 2019 – 2022 Continued investments and Globalization and strategic collaboration • Expanded into formulations development growth • Contract with Endo Pharmaceuticals to develop novel anti cancer • Expanded collaboration with biological therapeutic molecules BMS; Baxter and Amgen •
Slide 14: Our divisions
Our divisions Research business Development and Manufacturing business Discovery Services Dedicated R&D Centers Development Services Manufacturing Services Engaged in early-stage research, from Dedicated R&D facilities for Engaged in activities from pre-clinical Engaged in the manufacturing of targe
Slide 15: Our collaboration models
Our collaboration models 1 2 3 4 5 6 Dedicated R&D Labs FTE FFS Productivity based Risk-reward Delivery based contract • Dedicated scientific • Pre-defined • Client collaboration model • Across a portfolio of for CDMO business and support teams numbers of to deliver agreed • Offer the services stage
Slide 16: Our dedicated R&D centers exemplify the success of our long-term strategic alliances
Our dedicated R&D centers exemplify the success of our long-term strategic alliances • 600+ scientists • 300,000+ sq. ft. laboratory space • Largest R&D Center in Asia for BMS (est.d 2009). • Integrated drug discovery and development in multiple therapeutic areas, including cardiovascular, fibrosis,
Slide 17: Backed by world class state of the art infrastructure
Backed by world class state of the art infrastructure HQ Campus 90 acres in Bangalore where most of Syngene’s R&D Expansion Genome capabilities are Valley, Hyderabad, India housed today commenced operation in Aug 2019 API Mfg Expansion Commercial Manufacturing to Biologics Expansion support product
Slide 18: Agile and experienced workforce supported by our commitment to continuous learning
Agile and experienced workforce supported by our commitment to continuous learning ~6000 Environment that engages our 27% strong pool of employees employees and enables them to grow female employees vs 16% in FY16 Encouraging development of life skills ~5300 scientists delivering quality Enriching t
Slide 19: Harnessing digitization and automation
Harnessing digitization and automation Generating reliable and retrievable data by using advanced technology platforms. Online management of specifications, Online document procedures, policies, checklist, storage and issuance Online training platform which manuals, BMR, SMF, TTD, protocol, tracks l
Slide 20: Strategic Sourcing – agility and resilience that makes a difference
Strategic Sourcing – agility and resilience that makes a difference Our dedicated Strategic Sourcing professionals have the expertise and experience to work closely with our global supplier base to ensure timely delivery of supplies for smooth operations of the company, while ensuring strict adheren
Slide 21: Operational excellence is a way of life
Operational excellence is a way of life Building Right Philosophy Building Robust Process Building Sustenance Daily • LEAN & SIX SIGMA is a • Simplification of order- • Right culture with high Visual belt certification delivery processes. focus on safety, quality Board program wherein black • LEAN L
Slide 22: Strategic Advantages
3 Strategic Advantages Syngene
Slide 23: Syngene’s Strength
Syngene’s Strength Quality Focus • Quality driven organization A Global CRO/CDMO IP Position • Excellent track record of compliance with • Integrated Drug Discovery, Development and • IP can be fully assigned to clients global regulators Manufacturing service provider • Strong track record of Data I
Slide 24: Strong track record of growth and profitability
Strong track record of growth and profitability Total Revenue (Rs. Mn) EBITDA (Rs. Mn) Profit After Tax * (Rs. Mn) 8,489 26,570 6,995 7,364 4,211 22,489 6,119 3,662 3,821 20,935 3,316 19,007 5,266 3,054 14,849 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 to FY22 -
Slide 25: Multiple levers for growth going ahead
Multiple levers for growth going ahead Expand/Extend Existing Clients Capacity Expansion • High service integration • Consistent investment • Dedicated centers model • FTE services, manufacturing, formulation, biologics, stability Engage New Clients • Tailored service offerings and dedicated personn
Slide 26: Our end-to-end platform enables us to be a 'one-stop-shop'
Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small and large molecules) Discovery Development Manufacturing Small Drug Substance Chemistry Molecules Large Development Clinical Supplies Molecules Drug Product Development Biology Integrated D
Slide 27: Discovery Services
Discovery Services Target Identification and Hit HitHit to Lead to Lead Optimization Lead IND Enabling IND IND IND / Ph1 / DE Validation Identification Lead Optimization Enabling Ph1 DE Target ID In vitro assays: In In vitro vitro assays: assays: In Invivo vivoassays/studies: assays/studies: Later T
Slide 28: Development Services and Manufacturing Services
Development Services and Manufacturing Services Developability Development Clinical Phase Registration/process Commercial Assessment phase Phase I Phase II Phase III validation batches Early PK, MTD/DRF studies, • IND enabling GLP Tox studies: Ames, Chromosomal • NDA enabling studies: Sub- chronic a
Slide 29: Biologics Development and Manufacturing services
Biologics Development and Manufacturing services Developability Development Clinical Phase Registration/process Commercial Assessment phase Phase I Phase II Phase III validation batches • Cell line development / • Clone to GMP • Process DOE, robustness and safety study selection • Upstream process O
Slide 30: Led by a globally experienced management team
Led by a globally experienced management team Jonathan Hunt Dr. Mahesh Bhalgat Sibaji Biswas Ashu Tandon Sanjeev Sukumaran Managing Director and Chief Chief Operating Officer Chief Financial Officer Chief Commercial Officer Chief Human Resources Officer Executive officer Sanofi, Amgen, Vodafone, IQV
Slide 31: Advised by Our Board of Directors
Advised by Our Board of Directors Kiran Mazumdar Shaw Jonathan Hunt Dr. Carl Dcicco Professor Catherine Vinita Bali Non-Executive Managing Director and Chief Independent Director Rosenberg Independent Director Chairperson Executive officer Non-Executive Director Experience Chairperson of Biocon Limi
Slide 32: Committed to sustainability
Committed to sustainability Safety is at the heart of everything we do Committed to environmental protection • Accredited with ISO 45001:2018 for its Occupational Health and Safety • Accredited with ISO 14001:2015 for its effective Environment (OH&S) measures Management System (EMS) • Risk assessmen
Slide 33: ESG report
ESG report -a step towards delivering a transparent account of our progress on financial and non-financial parameters ENVIRONMENTAL SOCIAL GOVERNANCE • Environmental Governance through three • Safety • Quality assurance areas energy use, Water conservation, and • Centralized team of EHSS professiona
Slide 34: Industry recognition for our scientific capability and best practices
We have consistently received industry recognition for our scientific capability and best practices • Bio-Excellence Award 2018: At Bengaluru Tech • CMO Leadership Award Winner 2020 - under Summit, Bengaluru Categories: Capabilities, Compatibility, • CMO Leadership Awards 2022 • Best Bioprocessing E
Slide 35: Proactively managing risks through robust risk management framework
Proactively managing risks through robust risk management framework Syngene has a risk management framework to identify, monitor, report and manage risk across the business. Every risk owner monitors and manages risks relevant to their area of responsibility. Executive Committee (EC) Board of Direct
Slide 36: Financials
4 Financials
Slide 37: Q4 financial highlights
Q4 financial highlights Particulars Q4 FY22 Q4 FY21 YoY Change Q3 FY22 QoQ change Revenue from Operations 7,581 6,586 15% 6,414 18% Other Income 147 184 (20%) 129 14% Total Revenue 7,728 6,770 14% 6,543 18% Material and Power Costs 2,325 1,762 32% 1,898 22% Employee Costs 1,736 1,826 (5%) 1,888 (8%)
Slide 38: FY22 financial highlights
FY22 financial highlights Particulars FY22 FY21 YoY Change Balance Sheet Highlights Revenue from operations (excl export incentives) 26,042 21,843 19% Other Income 528 646 (18%) Total Revenue 26,570 22,489 18% As on 31st March 2022 Material and power costs 8,138 5,839 39% Employee costs 7,181 6,602
Slide 39: Shareholding and Share Information
Shareholding and Share 5 Information
Slide 40: Biocon Group and Syngene
Biocon Group and Syngene Biocon Limited, founded in 1978, is Syngene, a subsidiary of Biocon Limited, was Biocon Biologics, another subsidiary of an innovation-led global established in 1993 as India’s first Contract Biocon Limited, consolidates the biopharmaceuticals company Research Organization -
Slide 41: Shareholding and Share Information
Shareholding and Share Information Syngene’s Shareholding Pattern* Syngene’s Share Information* NSE Ticker SYNGENE 1% BSE Ticker 539268 Promoter & 29% Promoter Group Market Cap (Rs. Mn) 2,39,516 Public % free-float 29% Free-float market cap (Rs. Mn) 69,268 ESOP Trust 70% Share Outstanding (Mn) 401 3
Slide 42: For more details
For more details Visit our website www.syngeneintl.com https://twitter.com/SyngeneIntl https://www.linkedin.com/company/syngene-international-limited https://www.facebook.com/syngeneintl/ https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ IR Contact: Media Contact: Krishnan G Shotorupa Ghosh +
Slide 43: Thank you
Thank you © 2022 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the
Syngene International — Investor Presentation (April 2022) on 6ix